Decreased bone mineralization in children with Noonan syndrome: Another consequence of dysregulated RAS MAPKinase pathway?

被引:26
作者
Choudhry, Kiran S. [1 ]
Grover, Monica [1 ]
Tran, Alyssa A. [2 ]
Smith, E. O'Brian
Ellis, Kenneth J. [3 ]
Lee, Brendan H. [2 ,4 ]
机构
[1] Baylor Coll Med, Dept Pediat, Div Endocrinol & Metab, Houston, TX 77030 USA
[2] Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA
[3] Baylor Coll Med, Childrens Nutr Res Ctr, Houston, TX 77030 USA
[4] Baylor Coll Med, Howard Hughes Med Inst, Houston, TX 77030 USA
基金
美国国家卫生研究院;
关键词
Noonan syndrome; Bone mineral density; RAS-MAPK pathway; DXA; NEUROFIBROMATOSIS TYPE-I; DENSITY; MUTATIONS; TYPE-1; GROWTH; CELLS; NF1; DIFFERENTIATION; OSTEOCLASTS; ACTIVATION;
D O I
10.1016/j.ymgme.2012.04.003
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: Noonan syndrome (NS) is a disorder of RAS- mitogen activated protein kinase (MAPK) pathway with clinical features of skeletal dysplasia. This pathway is essential for regulation of cell differentiation and growth including bone homeostasis. Currently, limited information exists regarding bone mineralization in NS. Materials and methods: Using dual-energy X-ray absorptiometry (DXA), bone mineralization was evaluated in 12 subjects (mean age 8.7 years) with clinical features of NS. All subjects underwent genetic testing which showed mutations in PTPN11 gene (N = 8) and SOS! gene (N = 1). In a subgroup of subjects with low bone mass, indices of calcium-phosphate metabolism and bone turnover were obtained. Results: 50% of subjects had low bone mass as measured by DXA. Z-scores for bone mineral content (BMC) were calculated based on age, gender, height, and ethnicity. Mean BMC z-score was marginally decreased at -0.89 {95% CI -2.01 to 0.23; p = 0.1}. Mean total body bone mineral density (BMD) z-score was significantly reduced at -1.87 {95% CI -2.73 to -1.0; p = 0.001}. Mean height percentile was close to -2 SD for this cohort, thus total body BMD z-scores were recalculated, adjusting for height age. Adjusted mean total body BMD z-score was less reduced but still significant at -0.82 (95% CI -1.39 to -0.25: p = 0.009). Biochemical evaluation for bone turnover was unremarkable except serum IGF-I and IGF-BP3 levels which were low-normal for age. Discussion: Children with NS have a significantly lower total body BMD compared to age, gender, ethnicity and height matched controls. In addition, total BMC appears to trend lower in children with NS compared to controls. We conclude that the metabolic bone disease present resulted from a subtle variation in the interplay of osteoclast and osteoblast activity, without clear abnormalities being defined in the metabolism of either. Clinical significance of this finding needs to be validated by larger longitudinal studies. Also, histomorphometric analysis of bone tissue from NS patients and mouse model of NS may further elucidate the relationship between the RAS-MAPK pathway and skeletal homeostasis. (C) 2012 Elsevier Inc. All rights reserved.
引用
收藏
页码:237 / 240
页数:4
相关论文
共 32 条
  • [1] ANGUS RM, 1989, J AM DIET ASSOC, V89, P209
  • [2] Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells
    Bollag, G
    Clapp, DW
    Shih, S
    Adler, F
    Zhang, YY
    Thompson, P
    Lange, BJ
    Freedman, MH
    McCormick, F
    Jacks, T
    Shannon, K
    [J]. NATURE GENETICS, 1996, 12 (02) : 144 - 148
  • [3] Generalized metabolic bone disease in neurofibromatosis type I
    Brunetti-Pierri, Nicola
    Doty, Stephen B.
    Hicks, John
    Phan, Kelly
    Mendoza-Londono, Roberto
    Blazo, Maria
    Tran, Alyssa
    Carter, Susan
    Lewis, Richard Alan
    Plon, Sharon E.
    Phillips, William A.
    Smith, E. O'Brian
    Ellis, Kenneth J.
    Lee, Brendan
    [J]. MOLECULAR GENETICS AND METABOLISM, 2008, 94 (01) : 105 - 111
  • [4] Germline missense mutations affecting KRAS isoform B are associated with a severe Noonan syndrome phenotype
    Carta, Claudio
    Pantaleoni, Francesca
    Bocchinfuso, Gianfranco
    Stella, Lorenzo
    Vasta, Isabella
    Sarkozy, Anna
    Digilio, Cristina
    Palleschi, Antonio
    Pizzuti, Antonio
    Grammatico, Paola
    Zampino, Giuseppe
    Dallapiccola, Bruno
    Gelb, Bruce D.
    Tartaglia, Marco
    [J]. AMERICAN JOURNAL OF HUMAN GENETICS, 2006, 79 (01) : 129 - 135
  • [5] Costello syndrome: clinical diagnosis in the first year of life
    Digilio, M. Cristina
    Sarkozy, Anna
    Capolino, Rossella
    Testa, M. Beatrice Chiarini
    Esposito, Giorgia
    de Zorzi, Andrea
    Cutrera, Renato
    Marino, Bruno
    Dallapiccola, Bruno
    [J]. EUROPEAN JOURNAL OF PEDIATRICS, 2008, 167 (06) : 621 - 628
  • [6] Decreased bone mineral density in neurofibromatosis type I - Results from a pediatric cohort
    Dulai, Sukhdeep
    Briody, Julie
    Schindeler, Aaron
    North, Kathryn N.
    Cowell, Christopher T.
    Little, David G.
    [J]. JOURNAL OF PEDIATRIC ORTHOPAEDICS, 2007, 27 (04) : 472 - 475
  • [7] Bone metabolism markers and bone mineral density in children with neurofibromatosis type-1
    Duman, Ozgur
    Ozdem, Sebahat
    Turkkahraman, Doga
    Olgac, Nihal Dundar
    Aydin, Firat
    Haspolat, Senay
    [J]. BRAIN & DEVELOPMENT, 2008, 30 (09) : 584 - 588
  • [8] Z score prediction model for assessment of bone mineral content in pediatric diseases
    Ellis, KJ
    Shypailo, RJ
    Hardin, DS
    Perez, MD
    Motil, KJ
    Wong, WW
    Abrams, SA
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2001, 16 (09) : 1658 - 1664
  • [9] Noonan syndrome and related disorders: dysregulated RAS-mitogen activated protein kinase signal transduction
    Gelb, Bruce D.
    Tartaglia, Marco
    [J]. HUMAN MOLECULAR GENETICS, 2006, 15 : R220 - R226
  • [10] Osteoclasts derived from patients with neurofibromatosis 1 (NF1) display insensitivity to bisphosphonates in vitro
    Heerva, Eetu
    Peltonen, Sirkku
    Svedstrom, Erkki
    Aro, Hannu T.
    Vaananen, Kalervo
    Peltonen, Juha
    [J]. BONE, 2012, 50 (03) : 798 - 803